SMA Newsroom

SMA Europe press release

Novartis press release

The European Commission has granted marketing authorisation for Itvisma (intrathecal formulation of onasemnogene abeparvovec, developed by Novartis) for the treatment of adults and children aged 2 years and older living with 5q spinal muscular atrophy (SMA). 
&nbsp;

Breaking News: Novartis receives European Commission market authorisation for ITVISMA

Full Annual report 2025

SMA Europe Annual Report - 2025

We are pleased to launch SMA Europe&rsquo;s Annual report 2025.&nbsp;

SMA Europe launches the Annual report 2025

Please find the letter here

Community Letter from NMD Pharma: completion of its Phase 2 SYNAPSE-SMA clinical trial of ignaseclant (formerly NMD670)

Community letter Scholar Rock

FDA accepts to review Biologics License Application for apitegromab

FDA accepts to review Biologics License Application for apitegromab

Community Update: FDA accepts to review Biologics License Application for apitegromab

Categories